June 2019 - Volume 3 - Issue - Contributor Index

Author:
D, L.
Author:
D'Adda, M.

OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY: S882

Malagola, M.; Efficace, F.; Polverelli, N.; More

HemaSphere. 3:396-397, June 2019.

SECOND PRIMARY MALIGNANCIES IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: REAL WORLD EVIDENCE FROM 215 CONSECUTIVELY TREATED PATIENTS IN LOMBARDY: PS1462

Maffioli, M.; Giorgino, T.; Mora, B.; More

HemaSphere. 3:673-674, June 2019.

THE COMBINATION OF LOW ADAMTS-13 ACTIVITY AND HIGH ANTI-ADAMTS13 ANTIBODIES AT REMISSION HIGHLY PREDICTS DISEASE RELAPSE IN PATIENTS WITH ACQUIRED TTP: A MULTI-INSTITUTIONAL STUDY: S1646

Schieppati, F.; Russo, L.; Marchetti, M.; More

HemaSphere. 3:761-762, June 2019.

Author:
D'Alò, F.
Author:
D'Amore, F.

RITUXIMAB MAINTENANCE FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE REMISSION: RESULTS FROM A RANDOMIZED HOVON-NORDIC LYMPHOMA GROUP PHASE III STUDY: S1599

Lugtenburg, P.; Brown, P.; van der Holt, B.; More

HemaSphere. 3:736, June 2019.

Author:
D'Arco, A. M.
Author:
D'Arena, G.

THE USE OF THE BCL-2 INHIBITOR IN CLL PATIENTS WHO PROGRESSED AFTER B-CELL-RECEPTOR INHIBITORS: A RETROSPECTIVE MULTICENTER ITALIAN EXPERIENCE: PS1152

Innocenti, I.; Morelli, F.; Autore, F.; More

HemaSphere. 3:522-523, June 2019.

Author:
D'Argenio, M.
Author:
D'Ascola, D.
Author:
D'Ascola, D. G.
Author:
D'Auria, L.
Author:
D'Avola, A.
Author:
D'hont, I.

TARP AS IMMUNOTHERAPEUTIC TARGET IN AML EXPRESSED IN THE LSC COMPARTMENT: PF204

Depreter, B.; Weening, K.; Vandepoele, K.; More

HemaSphere. 3:54, June 2019.

Author:
D'Sa, S.

MAJOR RESPONSES IN MYD88 WILDTYPE (MYD88WT) WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB-3111): PF487

Dimopoulos, M.; Opat, S.; Lee, H.-P.; More

HemaSphere. 3:196, June 2019.

BORTEZOMIB-HIGH DOSE METHYLPREDNISOLONE OFFERS IMPROVED HAEMATOLOGICAL RESPONSES AND OVERALL SURVIVAL COMPARED TO BORTEZOMIB-DEXAMETHASONE IN SYSTEMIC LIGHT CHAIN AMYLOIDOSIS: PB2127

Mahmood, A. S.; Sachchithanantham, S.; Harrison, S.; More

HemaSphere. 3:958, June 2019.

Author:
D'Souza, A.
Author:
D‘Adda, M.
Author:
Da Ros, A.
Author:
da Rosa, L. I.

COMPREHENSIVE ANALYSIS OF BASELINE OUTCOME BIOPREDICTORS IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: THE ANCILLARY BIOLOGICAL STUDIES OF FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 CLINICAL TRIAL: PS1248

Ferrero, S.; Zaccaria, G. M.; Barbero, D.; More

HemaSphere. 3:569-570, June 2019.

Author:
Da Via, M.

HACE1, A NOVEL TUMOR SUPPRESSOR GENE WHICH REGULATE THE RESPONSE OF VENETOCLAX, GANT61 AND NECROPTOSIS ACTIVATORS BY CONTROLLING C-FLIP, GLI2 AND BCL2 GENES IN ACUTE MYELOID LEUKEMIA: PS1001

Garitano, A.; Teufel, E.; Kreckel, J.; More

HemaSphere. 3:450, June 2019.

Author:
Da Viá, M.
Author:
Daana, W.
Author:
Daar, S.
Author:
Daelemans, D.
Author:
Daffini, R.
Author:
Daga, S.
Author:
Dagdas, S.
Author:
Daguindau, N.

OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS, LYMA-101 TRIAL - A LYSA TRIAL: S103

Legouill, S.; Beldi-Ferchiou, A.; Cacheux, V.; More

HemaSphere. 3:3, June 2019.

Author:
Dahmash, F.
Author:
Dahotia, B.
Author:
dahpy, M.
Author:
Dai, D.

IVOSIDENIB (AG-120) INDUCES DURABLE REMISSIONS AND TRANSFUSION INDEPENDENCE IN PATIENTS WITH IDH1-MUTANT NEWLY-DIAGNOSED AML: UPDATED RESULTS FROM A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY: PS1025

Roboz, G. J.; DiNardo, C. D.; Stein, E. M.; More

HemaSphere. 3:461-462, June 2019.

IVOSIDENIB (AG-120) INDUCES DURABLE REMISSIONS AND TRANSFUSION INDEPENDENCE IN PATIENTS WITH IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME IN A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY: PS1337

Foran, J. M.; DiNardo, C. D.; Watts, J. M.; More

HemaSphere. 3:610-611, June 2019.

Author:
Dai, S.

PHASE II STUDY OF ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS): S839

Navada, S. C.; Garcia-Manero, G.; Atallah, E.; More

HemaSphere. 3:373-374, June 2019.

Author:
Dakik, H.
Author:
Dal, M. S.
Author:
Dal Bello, R.

MITOCHONDRIAL PRIMING OF BLASTS, BUT NOT LSC, PREDICTS SURVIVAL IN OLDER AML PATIENTS TREATED INTENSIVELY INDEPENDENTLY OF ONCOGENETICS: A STUDY ON THE ALFA 1200 TRIAL: PF211

Dal Bello, R.; Adès, L.; Braun, T.; More

HemaSphere. 3:57, June 2019.

Author:
Dal Bo, M.
Author:
Dal Lago, L.
Author:
Dal Molin, A.
Author:
Dalal, M.
Author:
Dalby-Brown, W.

TARGETING ONCOGENIC NOTCH1 IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH A NEW SELECTIVE SERCA INHIBITOR CAD204520: PF158

Marchesini, M.; Gherli, A.; Winter, A.-M. Lund; More

HemaSphere. 3:31, June 2019.

Author:
Dale, D. C.
Author:
Daley, J.

SIGNIFICANT POM EFFECT ON THE IMMUNE-CELL PROFILES IN B, T AND NK SUBSETS IN A LARGE COHORT CLINICAL TRIAL IN RELAPSED/REFRACTORY MYELOMA: PF588

Prabhala, R.; Samur, M.; Talluri, S.; More

HemaSphere. 3:246, June 2019.

Author:
Dalgaard, L. T.
Author:
Dalla Palma, B.

CARFILZOMIB LENALIDOMIDE DEXAMETHASONE (KRD) WITH OR WITHOUT TRANSPLANTATION IN NEWLY DIAGNOSED MYELOMA (FORTE TRIAL): EFFICACY ACCORDING TO RISK STATUS: S872

Gay, F.; Cerrato, C.; Scalabrini, Rota D.; More

HemaSphere. 3:390-391, June 2019.

Author:
Dalla-Pozza, L.
Author:
Dalle, J.-H.

SAFETY AND EFFICACY OF TISAGENLECLEUCEL (CTL019) IN B ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND YOUNG ADULTS: ROBERT DEBRÉ AND SAINT LOUIS HOSPITALS EXPERIENCE: PS943

Dourthe, M. E.; Cabannes-Hamy, A.; Yakouben, K.; More

HemaSphere. 3:425, June 2019.

Author:
Dally, N.
Author:
Dam, M. J.
Author:
Damaj, G.

OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS, LYMA-101 TRIAL - A LYSA TRIAL: S103

Legouill, S.; Beldi-Ferchiou, A.; Cacheux, V.; More

HemaSphere. 3:3, June 2019.

Author:
Damen, J.
Author:
Damianaki, A.

EVALUATION OF THE QUANTITATIVE CHARACTERISTICS OF MYELOID DERIVED SUPPRESSOR CELLS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND ASSOCIATED HYPOGAMMAGLOBULINEMIA: PB1881

Zavisanou, K.; Bizymi, N.; Ioneskou, K.; More

HemaSphere. 3:857, June 2019.

Author:
Damiani, D.

CORRELATION BETWEEN LEVELS OF EARLY MOLECULAR RESPONSE AND BCR-ABL TRANSCRIPT TYPE IN STABLE DMR ATTAINMENT IN CML PATIENTS TREATED WITH IMATINIB: PB1930

Tiribelli, M.; Bonifacio, M.; Binotto, G.; More

HemaSphere. 3:877-878, June 2019.

Author:
Damlaj, M.
Author:
Damm, F.

HARMONY ALLIANCE: EUROPEAN PUBLIC-PRIVATE DATA COLLECTION LEADS THE WAY - FIRST RESULTS OF THE “PROOF-OF-PRINCIPLE” STUDY IN ACUTE MYELOID LEUKEMIA: PS1003

Bullinger, L.; Valk, P.; Versluis, J.; More

HemaSphere. 3:451, June 2019.

Author:
Dammag, E.
Author:
Damy, T.
Author:
Dan, E.

SETD2 LOSS OF FUNCTION IS A RECURRENT EVENT IN ADVANCED-PHASE CHRONIC MYELOID LEUKEMIA INDUCED BY POST-TRANSLATIONAL MECHANISMS THAT CAN BE THERAPEUTICALLY TARGETED: S123

Mancini, M.; De Santis, S.; Monaldi, C.; More

HemaSphere. 3:13-14, June 2019.

Author:
Danaee, A.
Author:
Danek, P.
Author:
Dang, D.
Author:
Dang, P.
Author:
Dang, R.

SPLENECTOMY IN IMMUNE THROMBOCYTOPENIA: DO CHANGING TREATMENT PATTERNS FOR ITP AFFECT OUTCOMES? DATA FROM THE UK ITP REGISTRY: PF691

Todd, S.; Infirri, Sardo S.; Miah, H.; More

HemaSphere. 3:299-300, June 2019.

Author:
Danho, N. C.
Author:
Daniel, D.
Author:
Danilesko, I.
Author:
Danilina, A.
Author:
Danilov, A.
Author:
Danise, P.
Author:
Dannenmann, B.
Show: